The financial burden of PARP inhibitors on patients, payors, and financial assistance programs: who bears the cost?

OBJECTIVES: Poly(ADP-ribose) polymerase (PARP) inhibitors are expensive and their use is expanding. We aimed to evaluate cost sharing patterns between patients, payors, and financial assistance programs. METHODS: We identified ovarian cancer patients prescribed a PARP inhibitor from 5/2015–9/2019 us...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Gynecol Oncol
Asıl Yazarlar: Goldsberry, Whitney N., Summerlin, Sarah S., Guyton, Allison, Caddell, Brittani, Huh, Warner K., Kim, Kenneth H., Liang, Margaret I.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2021
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7902423/
https://ncbi.nlm.nih.gov/pubmed/33414026
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2020.12.039
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller